Compare SRPT & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | FSK |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2000 | 2008 |
| Metric | SRPT | FSK |
|---|---|---|
| Price | $21.06 | $11.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 29 | 8 |
| Target Price | ★ $25.85 | $13.19 |
| AVG Volume (30 Days) | 2.3M | ★ 3.1M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 18.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $2,198,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $267.30 |
| Revenue Growth | ★ 15.58 | N/A |
| 52 Week Low | $10.42 | $9.72 |
| 52 Week High | $64.80 | $22.68 |
| Indicator | SRPT | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 56.12 |
| Support Level | $20.61 | $9.85 |
| Resistance Level | $22.69 | $11.41 |
| Average True Range (ATR) | 0.90 | 0.35 |
| MACD | -0.18 | 0.04 |
| Stochastic Oscillator | 65.94 | 81.91 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.